WorkBeads used for full scale production of FDA approved drug
April 12, 2018 / erik abrahamsson
Press release April 12, 2018
Bio-Works’ separation media, WorkBeads, has become standard for the production of an FDA approved biopharmaceutical which is being used globally for treatment of patients. This pharmaceutical is the first of several ongoing pharmaceutical projects, where WorkBeads is being used, which has come all the way from lab scale to full scale production.
Bio-Works experiences a clear trend where an increasing number of the customers place re-occurring WorkBeads orders. The trend indicates that many of Bio-Works’ customers are moving closer to full scale production. The regulatory authorities often demand that the same separations media is used in production scale as has been used during the late clinical stage (phase 3). This means repeated orders and continuous revenue for Bio-Works during the life time of the pharmaceutical product.
Mats Johnson, Bio-Works CEO:
”We have for a long time worked intensively to commercialize WorkBeads. The fact that WorkBeads now is used for production of an FDA approved pharmaceutical is a breakthrough and a significant proof of confidence which will further strengthen the trust in our products. It decreases the threshold for the use of Bio-Works’ products in new projects. Going forward this breakthrough will lead to increased revenue for Bio-Works and to new sales opportunities.”
For more information please visit Bio-Works’ homepage, www.bio-works.com, or contact Mats Johnson, CEO for Bio-Works, e-mail: firstname.lastname@example.org, telephone: +46 70 516 53 37.
Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media. Bio-Works’ agarose based high performance products are used for purificationin the life science research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follows the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.